Schedule
Friday, May 28
8 - 12PM	Registration
8 - 12PM	Personnel Placement
7 - 3PM	Exhibits and Contributed Poster Presentations in Exhibit Hall
8 - 10:15AM	Contributed Workshops (3 sessions @ 35 minutes)
	See ­ CONTRIBUTED WORKSHOPS Section
10:30 - 12PM	Contributed Podium Presentations
	"ECONOMIC AND OUTCOMES ISSUES IN GI DISORDERS AND RENAL DISEASE" ECONOMIC AND CLINICAL OUTCOMES MODELS FOR THE EVALUATION OF DRUG THERAPY STRATEGIES IN TREATMENT OF GERD McGhan WF1, Smith MD2, Crawley JA3, 1Philadelphia College of Pharmacy and Science , Philadelphia, PA, USA; 2Health Decision Strategies, Princeton, NJ, USA; 3Astra Merck Inc., Wayne, PA, USA UPPER GASTROINTESTINAL SYMPTOMS AND NONCOMPLIANCE WITH DOSING INSTRUCTIONS ASSOCIATED WITH ALENDRONATE FOR OSTEOPOROSIS IN A LARGE HMO Ettinger B1, Schein JR2, Pressman A1, 1Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS IN GASTRIC ULCER Ikeda S, Ikegami N, Keio University, School of Medicine, Tokyo, Japan. PROSPECTIVE ECONOMIC EVALUATION IN A PHASE IIIb RENAL TRANSPLANT CLINICAL TRIAL Arnold RJG1, Pettit KG1, DiCesare J2, Fastenau J2, Kaniecki DJ1. 1Pharmacon International, Inc. New York, NY, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA ACUTE VARICEAL BLEEDING: FIRST-LINE INJECTION SCLEROTHERAPY AND SOMATOSTATIN Weißflog D1, Sauer B2, Darcis T3, Schwicker D4, Staritz M2. 1HealthEcon, Basle, Switzerland, 2Hospital Villingen-Schwenningen, Germany, 3UCB Pharma, Brussels, Belgium, 4PAREXEL International, Alexandria, VA, USA PREDICTORS OF DIAGNOSTIC RELATED GROUP DAY OUTLIERS IN THE MEDICARE END STAGE RENAL DISEASE POPULATION Vilas-Boas I. Centro de Estudos de Farmacoepidemiologia, Associação Nacional das Farmácias, Lisbon, Portugal "ECONOMIC AND OUTCOMES ISSUES IN INFECTIOUS DISEASE" RANDOMISED PROSPECTIVE STUDY COMPARING COST-EFFECTIVENESS OF TEICOPLANIN AND VANCOMYCIN AS SECOND-LINE EMPIRIC THERAPY FOR INFECTION IN NEUTROPENIC PATIENTS Domínguez-Gil A, Pérez M, Santos L, San Miguel JF, Vázquez L, Vilches P, Gutierrez N, García-Saiz R, Caballero D, Hospital Universitario de Salamanca, Salamanca, Spain WILLINGNESS TO PAY FOR HIV PREVENTION: A STUDY OF HIGH AND LOW-RISK GROUPS. Flanders S, Saint Louis University, School of Public Health, St. Louis, MO, USA. PRESCRIBING PATTERNS FOR TREATMENT OF UPPER RESPIRATORY INFECTIONS McLaughlin TP, Lalla DV and Kozma CM College of Pharmacy, The University of South Carolina, Columbia, SC, USA. EVALUATION OF THE COST-EFFECTIVENESS OF MANAGEMENT STRATEGIES IN CYTOMEGALOVIRUS INFECTION AND DISEASE Annemans L1, Mauskopf J2, Richter A2, Chulay J3, Maclaine G3, 1HEDM, Belgium; 2Research Triangle Institute, RTP, NC, USA; 3Glaxo Wellcome, RTP, NC, USA SOCIO-ECONOMIC RELEVANCE OF INPATIENT TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH TAZOBACTAM / PIPERACILLIN 0,5 g / 2,0 g IN COMPARISON WITH AMOXICILLIN / CLAVULANIC ACID, CEFTRIAXONE AND CEFOTAXIME Bruchhausen Y, Rappenhner B, Institute of Empirical Health Economics, Odenthal, Germany COST-EFFECTIVENESS OF LIPOSOMAL DAUNORUBICIN VERSUS LIPOSOMAL DOXORUBICIN IN KAPOSI SARCOMA. Egan,T1 Henry, H2. 1Philadelphia College of Pharmacy and Science, Philadelphia, PA 2Graduate Hospital, Philadelphia, PA, USA "METHODOLOGY AND GUIDELINE DEVELOPMENT ISSUES" IMPROVING CLINICAL OUTCOMES BY INTEGRATING A NORMALIZED, STANDARDIZED, COMPARATIVE DATABASE INTO THE PROCESS OF CLINICAL QUALITY IMPROVEMENT. Bryant D1, Mignardi W1, Seltzer J2, 1Premier, Inc., Charlotte, NC, USA, 2Premier Research Worldwide, Philadelphia, PA, USA DISEASE MANAGEMENT IN HYPERTENSION: THE BENEFITS OF MEETING GUIDELINE GOALS FOR BLOOD PRESSURE Huse DM1, Usry CA2, Hartz SC1, 1Medical Research International, Burlington, MA, USA, 2Astra Merck Inc., Wayne, PA, USA. A NEW PARADIGM FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE. A SOCIAL-CLINICAL MODEL Wan GJ, Counte MA, Cella DF. Merck & Co., Inc., West Point, PA, USA. A RETROSPECTIVE APPROACH TO EVALUATE QALY: ESTIMATION OF HEALTH UTILITY INDEX FROM THE SF-36 IN A MANAGED CARE POPULATION Sengupta N, Nichol M. University of Southern California, LosAngeles, CA, USA. HEALTH UTILITIES INDEX: FURTHER EVIDENCE OF RESPONSIVENESS Torrance GW1,2, Feeny D1, Furlong W1, Barr RD1, DePauw S1, 1McMaster University, Hamilton, Ontario, Canada. 2Innovus Research Inc., Burlington, Ontario, Canada. SURVEY STRATEGIES IN THE REVISION OF THE GUIDELINES FOR ECONOMIC EVALUATION: CANADA Glennie JL, Baladi JF, Berka C, Hubbard E, Menon D, Otten N, Riviere M, Torrance G; The CCOHTA Guidelines Review Committee, Ottawa, Ontario, Canada.
1:30 - 3PM	Contributed Podium Presentations
	"ECONOMIC AND OUTCOMES ISSUES IN CRITICAL CARE" SOCIO-ECONOMIC EFFICIENCY OF PROPHYLAXIS OF EXACERBATIONS WITH N-ACETYLCYSTEINE IN PATIENTS WITH CHRONIC BRONCHITIS Rappenhöner B, Bachinger A, Rychlik R. Institute of Empirical Health Economics, Odenthal, Germany COST OF PREVENTABLE ADVERSE DRUG EVENTS IN EMERGENCY DEPARTMENT PATIENTS Dominguez-Gil A, Bajo A, Otero MJ, Garcia-Gutierrez JF, Hospital Universitario de Salamanca, Salamanca, Spain. MODELING SIDE EFFECT COSTS FROM LITERATURE-BASED DATA: STEROID-INDUCED SIDE EFFECTS IN RENAL TRANSPLANTATION Veenstra DL, Stergachis A, and Sullivan SD, University of Washington School of Pharmacy, Seattle, WA, USA. COST-BENEFIT ANALYSIS OF RECOMBINANT ERYTHROPOIETIN IN PREMATURE NEONATES Wandstrat TL; Maxwell SR. West Virginia University, Charleston, WV, USA. INCREMENTAL COST-EFFECTIVENESS ANALYSIS COMPARING 4-LAYER BANDAGE SYSTEM WITH AND WITHOUT APLIGRAF FOR THE OUTPATIENT TREATMENT OF VENOUS LEG ULCERS Attard C1, MacNeil P2, Sibbald GR3, Torrance GW1,4, Walker V1, 1Innovus Research Inc., Burlington, Ont., Canada, 2(Formerly) Novartis Pharmaceuticals Canada Inc., Dorval, Que., Canada, 3University of Toronto, Toronto, Ontario, Canada, 4McMaster University, Hamilton, Ontario, Canada DEVELOPMENT OF ASTHMA-SPECIFIC OUTCOMES MEASURES FOR CHILDREN Sweeny SF1, Lucas DO2, Creer TL3, French, DJ4. 1Research Triangle Institute, Research Triangle Park, NC, USA, 2Glaxo Wellcome, Inc, Research Triangle Park, NC, USA 3Ohio University, Athens, OH, USA, 4University of Western Australia, Medlands, Australia "ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH" A MODEL OF PRIMARY CARE TREATMENT OF MAJOR DEPRESSIVE DISORDER Bell EJ, Sullivan SD, Ramsey SD, Neil NJ, Veenstra DL, and Stergachis A. University of Washington MEDICAL AND ECONOMIC OUTCOMES OF NONCOMPLIANCE WITH DILANTIN IN ADULT MEDICAID EPILEPTICS Singer ME, Case Western Reserve University, Cleveland, OH USA FACTORS PREDICTING POTENTIALLY INAPPROPRIATE PSYCHOTROPIC PRESCRIBING FOR THE ELDERLY Aparasu RR, Mort JR, South Dakota State University, Brookings, SD USA TESTING THE RELIABILITY OF GENERIC QUALITY OF LIFE MEASURES IN THE STUDY OF MULTIPLE SCLEROSIS Holmes J, Kind P, Economists Advisory Group Limited, London, UK THE EUROQOL IN PARKINSON'S DISEASE RESEARCH: RATED CURRENT HEALTH VS. POPULATION-DERIVED HEALTH STATE PREFERENCES Chrischilles EA, Rubenstein LM, Voelker MD, The University of Iowa Department of Preventive Medicine and Environmental Health, Iowa City, IA USA "METHODOLOGY AND GUIDELINE DEVELOPMENT ISSUES"  POOR ADHERENCE TO HYPERTENSION TREATMENT GUIDELINES: AN ANALYSIS OF THERAPEUTIC CHOICES Huse DM1, Roht LH2, Hartz SC1, 1Medical Research International, Burlington, MA, 2Hoechst Marion Roussel, Kansas City, MO, USA. THE UTILIZATION AND COSTS OF PRESCRIPTION DRUGS IN A TEXAS MEDICAID MANAGED CARE PILOT PROGRAM Johnsrud MT, Lawson KA, The University of Texas at Austin, Austin, TX, USA POSTMARKETING OUTCOMES STUDIES: BENEFITS AND RISKS Garfield FB, Caro JJ, Caro Research, Boston, MA, USA RELATIONSHIP BETWEEN QUALITY OF LIFE, DISEASE SEVERITY AND PHYSICIAN VISITS IN MANAGED CARE PATIENTS WITH ATOPIC DERMATITIS Fagan S1, Frech F2, Pettit KG3, Bailey E1, Kaniecki DJ3, Arnold RJG3, Fivenson D1. 1Henry Ford Hospital, Detroit, MI; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ; 3Pharmacon International, Inc., New York, NY, USA. ADHERENCE OF HEALTH CARE WORKERS TO HEPATITIS B VACCINATION (HBV) POLICY IS INFLUENCED BY LEADERSHIP. Sutton EL, DoD Pharmacoeconomic Center, Fort Sam Houston, Tx, USA FORMULARY IMPACT DECISION MODELING IN HMG-COA REDUCTASE INHIBITORS Corey R, Sung JCY, Novartis Pharmaceuticals Corp. East Hanover, NJ, USA.
3 - 4:30PM	Fourth General Session
	"ISPOR Consensus Development Advisory Panel Reports" Moderator: Jean Paul Gagnon PhD, Director Developing Consensus on Pharmacoeconomic Methodology Clinical Studies Advisory Panel Report ­ Chairs: Margaret Healey PhD, Institute for Research & Education, HealthSystems Minneapolis & Patricia Deverka MD, MS, Hastings Research. Modeling Studies Advisory Panel Report ­ Chairs: Joseph Jackson PhD, Bristol-Myers Squibb & Joel Hay PhD, University of Southern California Retrospective and Claims Data Studies Advisory Panel Report ­ Chairs: Renee Goldberg Arnold PharmD, Pharmacon International & James G. Kotsanos MD, MS, Eli Lilly and Company Developing Consensus on Pharmacoeconomic Education and a Code of Ethics Education and Skills Advisory Panel Report ­ Chairs: Katie Copley-Merriman MS, MBA, Parke-Davis & Gordon Vanscoy PharmD, MBA, Stadtlander Drug Company, Inc. Bias, Credibility, and Quality Advisory Panel Report ­ Chairs: J. Rodney Barnes MBA, Pharmacia & Upjohn & Alan Heaton PharmD, Pharmacy Gold Inc. Developing Consensus on How to Communicate Pharmacoeconomic Results Pharmacoeconomic Applications Advisory Panel Report ­ Chairs: Jon Clouse RPh, MS, United Health Care Corporation & Jean Paul Gagnon PhD, Hoechst Marion Roussel Communicating and Reporting ­ Advisory Panel Report ­ Chairs: Alan Bakst PharmD, Smith Kline Beecham & Elaine Power MPP, Agency for Health Care Policy and Research
4:30 - 5PM	Rapporteur
	Hugh Tilson MD, PhD, Glaxo-Wellcome